# Nanospectra Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanospectra-biosciences

- Industry: Biotechnology
- Headquarters: Houston, US
- Website: www.nanospectra.com
- Total disclosed funding: $1.7M
- Latest round: Series A (Oct 30, 2006)
- Investors on record: 1

## About

Nanospectra Biosciences, Inc. is a medical technology firm that specializes in innovative cancer treatment solutions using nanoshell technology, specifically through its AuroLase Therapy System.Founded in 2002 and headquartered in Houston, US, Nanospectra Biosciences focuses on developing advanced therapies for oncology. The company has undergone significant development in its product offerings but has not reported any notable pivots in its business strategy. Nanospectra has secured funding through multiple rounds, with its most recent funding round being a Series B, which raised USD 3.000 mn in September 2020, led by Sirtex Medical Limited. The total amount raised to date is USD 3.000 mn.Nanospectra specializes in advanced medical technologies leveraging nanoshells, specifically focusing on its core product, the AuroLase Therapy System. This innovative system utilizes gold nanoshells to target and destroy cancerous tissues through laser-induced thermal therapy, providing a minimally invasive treatment option for patients. The end use cases primarily involve oncology, addressing various cancers while aiming to reduce collateral damage to surrounding healthy tissues. The AuroLase Therapy is particularly designed for use in the treatment of tumors located in sensitive areas, enhancing efficacy and safety. The company's clientele includes hospitals, specialized cancer treatment centers, and medical professionals in North America and select markets in Europe, where the demand for advanced cancer therapies is growing.Nanospectra's revenue model is primarily based on direct sales of its proprietary AuroLase Therapy System to healthcare institutions and partnerships with medical facilities. Transactions typically involve the sale of the device along with accompanying service contracts for maintenance and training, ensuring that healthcare providers can effectively utilize the technology in patient care. The structure includes upfront payments for the equipment coupled with recurring revenue through service agreements. Pricing strategies may vary based on specific client needs and the scale of purchase, but details regarding individual pricing are confidential. The focus remains on establishing long-term relationships with healthcare providers, facilitating ongoing support and enhancements of the therapy system in the clinical setting.Nanospectra plans to leverage its recent Series B funding of USD 3.000 mn, raised in September 2020, to further develop its product offerings and expand into new markets. The company is designing upcoming enhancements to the AuroLase Therapy System, although specific release dates have not been disclosed. Additionally, Nanospectra aims to expand its presence in Europe and other international markets by 2023, tapping into the rising demand for innovative cancer therapies.

## Funding rounds

- Series A, Oct 30, 2006, $1.7M — Mercury Partners

## Investors

- Mercury Partners — Series A